Top Stories: Flexion Therapeutics, Inc. (NASDAQ:FLXN), Incyte Corporation (NASDAQ:INCY), Mad Catz Interactive Inc. (NYSEMKT:MCZ), SunEdison, Inc. (NYSE:SUNE), Alder Biopharmaceuticals Inc. (NASDAQ:ALDR)

Flexion Therapeutics, Inc. (NASDAQ:FLXN) belongs to Healthcare sector. Its weekly performance is 12.03%. On last trading day company shares ended up $23.74. Flexion Therapeutics, Inc. (NASDAQ:FLXN) distance from 50-day simple moving average (SMA50) is 17.45%. Flexion Therapeutics (NASDAQ:FLXN) was downgraded by Zacks from a “buy” rating to a “hold” rating in a research note issued on Wednesday.

Incyte Corporation (NASDAQ:INCY) shares advanced 0.20% in last trading session and ended the day at $108.33. INCY Gross Margin is 99.00% and its return on assets is -8.50%. Incyte Corporation (NASDAQ:INCY) quarterly performance is 15.48%. On 7 July, Incyte Corporation (NASDAQ:INCY) has agreed to fund a portion Vanderbilt University Medical Center’s cancer research under a multi-year partnership agreement.

On 10 July, Mad Catz Interactive Inc. (NYSEMKT:MCZ) shares advanced 2.25% and was closed at $0.41. MCZ EPS growth in last 5 year was -2.60%. Mad Catz Interactive Inc. (NYSEMKT:MCZ) year to date (YTD) performance is -2.62%. On 6 July, Mad Catz Interactive Inc. (NYSEMKT:MCZ) said that, its next great hope Rockband 4, and all the associated games controllers that it will help sell.

SunEdison, Inc. (NYSE:SUNE) shares moved up 4.07% in last trading session and ended the day at $30.41. SUNE Gross Margin is 9.20% and its return on assets is -8.60%. SunEdison, Inc. (NYSE:SUNE) quarterly performance is 13.94%.On 2 July, SunEdison, Inc. (NYSE:SUNE) and Gamesa Corp. Tecnologica SA, Spain’s largest turbine producer, have agreed to form a joint venture to develop as much as 1 gigawatt of wind power by 2018.

Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) shares advanced 8.63% in last trading session and ended the day at $49.86. ALDR return on assets is -0.30%. Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) quarterly performance is 78.58%.On 30 June, Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 674,157 shares of common stock.

Leave a Reply

Your email address will not be published. Required fields are marked *